The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity  by Broeders, Evie P.M. et al.
Clinical and Translational ReportThe Bile Acid Chenodeoxycholic Acid Increases
Human Brown Adipose Tissue ActivityGraphical AbstractHighlightsd The bile acid CDCA increases human BAT activity
d CDCA increases mitochondrial uncoupling in human primary
adipocytes derived from BAT
d CDCA promotes mitochondrial uncoupling via TGR5Broeders et al., 2015, Cell Metabolism 22, 418–426
September 1, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.07.002Authors
Evie P.M. Broeders, Emmani B.M.
Nascimento, Bas Havekes, ..., Bart
Staels, Wouter D. van Marken
Lichtenbelt, Patrick Schrauwen
Correspondence
p.schrauwen@maastrichtuniversity.nl
In Brief
While cold is an effective strategy to
activate brown fat, alternative
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The interest in brown adipose tissue (BAT) as a target
to combat metabolic disease has recently been
renewed with the discovery of functional BAT in hu-
mans. In rodents, BAT can be activated by bile acids,
which activate type 2 iodothyronine deiodinase (D2)
in BAT via the G-coupled protein receptor TGR5,
resulting in increased oxygen consumption and
energy expenditure. Here we examined the effects
of oral supplementation of the bile acid chenodeoxy-
cholic acid (CDCA) on human BAT activity. Treatment
of 12 healthy female subjects with CDCA for 2 days
resulted in increased BAT activity. Whole-body
energy expenditure was also increased upon CDCA
treatment. In vitro treatment of primary human
brown adipocytes derived with CDCA or specific
TGR5 agonists increased mitochondrial uncoupling
and D2 expression, an effect that was absent in
human primary white adipocytes. These findings
identify bile acids as a target to activate BAT in
humans.
INTRODUCTION
Since the discovery in 2009 that humans possess functional
depots of brown adipose tissue (BAT) (Cypess et al., 2009; Saito
et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen et al.,
2009), many studies have been initiated to identify novel molec-
ular targets for the activation of BAT. We have previously shown
that acute cold exposure is a very potent activator of human BAT418 Cell Metabolism 22, 418–426, September 1, 2015 ª2015 Elsevie(van Marken Lichtenbelt et al., 2009), whereas cold acclimation
is able to recruit BAT in human volunteers (van der Lans et al.,
2013; Yoneshiro et al., 2013). Cold may activate BAT via activa-
tion of the SNS, and some studies have suggested that beta-
agonist treatment may be able to activate BAT in humans
(Cannon and Nedergaard, 2004), although this has not been
confirmed by others (Vosselman et al., 2012). However, due to
unwanted side effects, these interventions are not easily
applicable in humans, urging the search for novel activators of
human BAT.
Bile acids (BAs) are essential factors in lipid metabolism and
end products of cholesterol catabolism (Lefebvre et al., 2009;
Watanabe et al., 2006), the latter being the most important route
for elimination of surplus cholesterol from the circulation (Chen
et al., 2011). BAs are natural ligands for the nuclear farnesoid X
receptor (FXR) (Kawamata et al., 2003; Maruyama et al., 2002),
which controls the synthesis and enterohepatic circulation of
BAs by adjusting the expression of essential gene components
involved in BA synthesis, transportation, conjugation, and
detoxification (Houten and Auwerx, 2004; Russell, 2003). More
recently, several studies have also implicated a role for BAs in
the regulation of energy metabolism (Fiorucci et al., 2009; Hof-
mann, 2009; Lefebvre et al., 2009), and FXR agonists as well
as the FXR-target FGF19 have been suggested for the treatment
of themetabolic syndrome (Fu et al., 2004; Kir et al., 2011;Miyata
et al., 2012; Prawitt and Staels, 2010; Staels and Prawitt, 2013;
Tomlinson et al., 2002). Next to activation of FXR, BAs signal
through another pathway involving TGR5. In BAT, BAs activate
the TGR5 G protein-coupled receptor, resulting in increased
concentrations of the second messenger cAMP. Elevated
concentrations of cAMP activate type 2 deiodinase (D2), which
converts the inactive thyroid hormone thyroxine to active 3-5-
30-triiodothyronine, thereby resulting in increased BAT activity
and enhanced energy expenditure in murine BAT and humanr Inc.
Table 1. Skin Perfusion, Blood Pressure, and Body Temperatures
and Fasting Plasma Levels under Thermoneutral Conditions after
Placebo and CDCA Administration
Placebo CDCA
Mean skin temperature (C) 33.8 ± 0.7 33.5 ± 1.1
Core temperature (C) 37.4 ± 0.1 37.3 ± 0.3
Gradient core-mean skin (C) 3.3 ± 1.3 3.3 ± 1.4
Insulin (mU/ml) 7.6 ± 2.3 7.2 ± 3.5
Glucose (mM) 4.7 ± 0.3 4.7 ± 0.3
Free FAs (mM) 746 ± 268 586 ± 214a
Triglycerides (mM) 1,228 ± 575 1,227 ± 612
TSH (U/l) 1.4 ± 0.8 1.7 ± 1.3
FT4 (pmol/l) 14.1 ± 1.3 13.7 ± 1.1
FT3 (pmol/l) 1.6 ± 0.4 1.6 ± 0.4
CRP 5.2 ± 9.0 2.2 ± 2.3
Total bile acids (mM) 1.24 ± 0.81 12.47 ± 17.82a
Total CDCA (mM) 0.45 ± 0.38 10.30 ± 5.41a
Total CA (mM) 0.27 ± 0.33 0.15 ± 0.13
Total DCA (mM) 0.30 ± 0.23 0.42 ± 0.28
Total LCA (mM) 0.06 ± 0.00 0.08 ± 0.02
Total UDCA (mM) 0.08 ± 0.08 0.14 ± 0.12a
Total HCA (mM) 0.07 ± 0.09 0.15 ± 0.06a
Results are expressed asmeans ± SD. The effect of CDCA administration
was tested with a paired-samples t test.
ap < 0.05, n = 12.skeletal muscle (Watanabe et al., 2006). Indeed, the primary BA
cholic acid increases whole-body energy expenditure in mice
(Teodoro et al., 2014; Watanabe et al., 2006). Also in humans,
an effect of BAs on energy expenditure has been proposed.
Thus, the changes in circulating BAs have been correlated with
changes in energy and substrate metabolism upon Roux-en-Y
gastric bypass surgery (Ahmad et al., 2013; De Giorgi et al.,
2014; Kohli et al., 2013; Patti et al., 2009; Simonen et al.,
2012). In a study performed in healthy volunteers and patients
with liver cirrhosis, a positive correlation between circulating
BAs and energy expenditure was reported (Ockenga et al.,
2012). However, the use of the BA sequestrant colesevelam
was without effect on resting energy expenditure (Brufau et al.,
2010). So far, no effects of BA on BAT activity in humans have
been demonstrated, but a recent study in mice showedCBA
Cell Meenhanced BAT thermogenesis when using chenodeoxycholic
acid (CDCA) (Teodoro et al., 2014).
Here we investigated if increasing circulating BA levels upon
treatment of humans with CDCA would lead to an activation of
BAT activity and energy expenditure in human volunteers. To
investigate if the effect of CDCA onBAT activity can be attributed
to direct activation of human BAT, we cultured adipocytes from
the human ‘‘BAT’’ region and examined if CDCA could enhance
mitochondrial uncoupling and whether these effects are TGR5-
or FXR-specific. We show that the BA CDCA increases BAT
activity in humans via a TGR5-dependent mechanism.RESULTS AND DISCUSSION
Effect of CDCA Supplementation on Circulating
BA Levels
To investigate the effect of CDCA supplementation on energy
expenditure and BAT activity, we performed a placebo-
controlled crossover design study, in which healthy young
female volunteers ingested for 2 subsequent days 15 mg/kg
CDCA or placebo in the morning after an overnight fast. None
of the subjects reported nausea or diarrhea during the course
of the study. Fasting total BA levels increased from 1.24 ±
0.81 mM in the placebo intervention to 12.47 ± 17.82 mM in the
CDCA intervention group. Plasma levels of CDCA increased
approximately 23-fold after CDCA treatment (from 0.45 ±
0.38 mM to 10.30 ± 5.41 mM, p < 0.05, Table 1). In contrast, no
or only minor changes in absolute levels of the other BA were
seen upon CDCA treatment (Figures 1A and 1B, Table 1).
CDCA treatment resulted in a significant decline in fasting FFA
levels, whereas other blood parameters were unaffected, as
summarized in Table 1. These results thus confirm that the inter-
vention was successful in raising circulating CDCA levels.Effect of CDCASupplementation onWhole-Body Energy
Expenditure
Next, we investigated the effect of 24-hr CDCA treatment on
whole-body energy expenditure. Therefore, subjects stayed in
the respiration chamber for 24 hr. CDCA treatment did not
increase 24-hr energy expenditure (5.7 ± 0.7 kJ/min during
placebo intervention versus 5.9 ± 0.9 kJ/min during CDCA inter-
vention, p = 0.735). Since 24-hr energy expenditure can be
confounded by small changes in, for example, physical activity,
we also examined basal metabolic rate the next morning afterFigure 1. Composition of Bile Acid Pool
and Energy Expenditure Following CDCA
Intervention
(A and B) Composition of the total bile acid pools
in the placebo intervention (A) and CDCA inter-
vention (B) measured by standard LC-MS/MS.
CA, cholic acid; CDCA, chenodeoxycholic acid;
DCA, deoxycholic acid; LCA, litocholic acid;
UDCA, ursodeoxycholic acid; HCA, hyocholic
acid (n = 12).
(C) Basal metabolic rate after 24-hr intervention
with bile acid CDCA. *p < 0.05 (n = 12).
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Figure 2. BAT Activity Following CDCA Intervention
(A–C) Representative PET/CT (upper pictures), CT (middle pictures), and PET (lower pictures) scans of one subject after mild cold exposure (A), placebo (B), and
CDCA (C) intervention. The cubes indicate the VOIs with maximum [18F]FDG uptake.
(D and E) BAT SUV mean (D) and BAT SUV max (E) were measured under thermoneutral conditions.
(F) [18F]FDG uptake in BAT, WAT, muscle, and liver after placebo and CDCA intervention. *p < 0.05 (n = 12). Results are expressed as mean ± SEM.ingestion of the second dose of 15 mg/kg CDCA or placebo.
Basal metabolic rate was significantly higher by approximately
5% after CDCA administration compared to the placebo
intervention (4.5 ± 0.6 kJ/min versus 4.3 ± 0.6 kJ/min, p < 0.05,
Figure 1C). Although no long-term effects of CDCA on body
weight have been described so far, theoretically a permanent
5% increase in resting metabolic rate could have major effects
on body weight regulation and metabolic health if it would not
be compensated by increased energy intake.
Effect of CDCA Supplementation on BAT Activity
Recently, functional brown adipose tissue was discovered in
adult humans (Cypess et al., 2009; van Marken Lichtenbelt
et al., 2009; Virtanen et al., 2009). However, the role of BAT acti-
vation in the battle against the negative metabolic health effects
of obesity still needs to be established. Moreover, alternative
ways to activate BAT in humans are needed, as cold exposure
may not be the strategy of first choice to combat obesity and
its complications. We therefore next examined if CDCA treat-
ment increases BAT activity under thermoneutral conditions420 Cell Metabolism 22, 418–426, September 1, 2015 ª2015 Elsevie(i.e., in the basal state). Therefore, we performed PET-CT scan-
ning 3 hr after the last ingestion of placebo and CDCA, under
thermoneutral conditions (e.g., Figures 2B and 2C). We found
that both BAT mean standardized uptake values (SUVmean)
(from 0.8 ± 0.3 to 1.2 ± 0.3, p < 0.05, Figure 2D) and BAT SUV
max (from 1.0 ± 0.4 to 1.6 ± 0.4, p < 0.05, Figure 2E) were
increased after CDCA ingestion, whereas 18-Fluoro-Deoxy-
Glucose ([18F]FDG) uptake in skeletal muscle, subcutaneous
white adipose tissue (WAT), and the liver did not change (Fig-
ure 2F). Although a strong relation between BA and BAT activity
and NST has been confirmed in rodents (Watanabe et al., 2006),
human evidence for such relation is still lacking. In the current
study, we show in adult human subjects a highly significant acti-
vation of BAT upon administration of 15 mg/kg body weight
CDCA compared to placebo, which was accompanied by a sig-
nificant 5%–6% increase in energy expenditure in the basal,
resting state. However, it should be noted that it cannot be
excluded that BAs increase energy expenditure via BAT-inde-
pendent mechanisms. Furthermore, apart from its thermogenic
potential, BAT has also been associated with improved glucoser Inc.
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Figure 3. Gene and Protein Expression in
Adipocytes Derived from WAT and BAT
Biopsies
(A–G) mRNA expression of UCP1 (A), HOXC9 (B),
AP2 (C), TBX1 (D), TGR5 (E), and PGC1a (F)
was determined in adipocytes differentiated from
WAT and BAT biopsies. UCP1 protein was de-
tected using western blot techniques in adipo-
cytes derived from BAT biopsies (G). mRNA
expression was calculated using the 2DDCt
method. Results are expressed as mean ± SEM
(n = 3–4). *p < 0.05and lipid handling (Bartelt et al., 2011; Muzik et al., 2012; Orava
et al., 2011), but the effects of CDCA on substrate handling could
not be tested in this short-term proof-of-concept study. Clearly,
long-term human clinical intervention follow-up studies are
needed to examine if a sustained activation of BAT activity—
probably by other means than CDCA (see below)—is translated
into beneficial metabolic health effects.
Although BAT activity increased significantly upon CDCA
administration under thermoneutral conditions, the activation
of BAT upon CDCA was still markedly less than what could be
achieved by an acute cold exposure. Indeed, as a positive
control, we measured in all subjects, on a separate test day,
cold-activated BAT activity, which revealed that in all subjects
BAT could be activated by mild cold exposure (e.g., Figure 2A).
As expected, cold exposure had more marked effects on BAT
activity as shown by the SUV mean (5.2 ± 3.6) and SUV max
(7.2 ± 5.4) values. In fact, acute cold increases BAT activity by
400% compared to thermoneutral conditions, indicating that
the maximal achievable activation in these subjects far exceeds
the effects of CDCA. To allow the measurement of low BAT
activity under thermoneutral conditions upon CDCA or placebo,
we used the fixed volumemethod (van der Lans et al., 2014), andCell Metabolism 22, 418–426, Sas a result total BAT volume could not
be determined. Therefore, the effect of
CDCA on total BAT activity is difficult to
estimate. It is important to note that
CDCA may not be the most potent BA
to activate BAT nor to activate TGR5;
the choice to use CDCA in the current
study was solely based on the fact that
this compound is registered as a drug
and could therefore be safely adminis-
tered to our human volunteers as a proof
of concept that BA are able to activate
BAT in humans. Therefore, other BA or
TGR5 agonist could be tested for the
effects on BAT activity in humans.
CDCA Has Direct Effects on
Mitochondrial Uncoupling in
Human Brown Adipocytes
From rodent and cell experiments, it is
suggested that BAs may have a direct
effect on BAT metabolism via interaction
with the TGR5 receptor. Since CDCAmay not be the most potent BA to activate BAT and more potent
TGR5 agonists are in clinical development, we next wanted to
establish if the effects of CDCA ingestion on BAT activity
observed in our human intervention could be due to direct effects
on human brown adipocytes via TGR5 activation. To this end,
we employed a human in vitro model and prepared human
adipose tissue samples from subcutaneous fat and from the
prevertebral BAT region. Samples were obtained during thyroid
surgery and both white and BAT samples were taken from the
same subject. Mature adipocytes were differentiated from the
isolated stromal vascular fractions. To characterize the differen-
tiated cells, we measured mRNA expression levels of brown/
beige and white adipose tissue markers. mRNA expression
levels of the brown/beige markers UCP1, TBX1, and TGR5
were significantly higher in adipocytes derived from BAT bi-
opsies (Figures 3A, 3D, and 3E), whereas the white adipocyte
marker HOXC9 was significantly higher in adipocytes derived
from WAT biopsies (Figure 3B). Furthermore, UCP1 protein
abundance was also higher in adipocytes derived from BAT
biopsies (Figure 3G). We next measured oxygen consumption
in these in vitro differentiated cultured adipocytes while ATP syn-
thase was blocked using oligomycin (state 4o), thereby focusingeptember 1, 2015 ª2015 Elsevier Inc. 421
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Figure 4. CDCA Increases Mitochondrial Respiration in BAT In Vitro in a TGR5-Dependent Manner
(A–J) Respiration was measured in oligomycin (OG)-treated white adipocytes (white circles) and brown adipocytes (black circles) following 1 mM norepinephrine
(A), 30 mMCDCA (B), 10 mMCDCA (C), 3 mMCDCA (D), 10 mM LCA (E), 3 mM LCA (F), 1 mM LCA (G), 30 mM TGR5 agonist CpdA (H), 3 mM TGR5 agonist CpdA (I),
or 3 mM FXR agonist GW4064 (J) at t = 61 min, indicated by the upward pointing arrow. Results are expressed as mean ± SEM. *p < 0.05 (n = 3–4). See also
Figures S1 and S2.on the capacity for mitochondrial uncoupling. As a proof of
concept that human primary brown adipocytes have capacity
for mitochondrial uncoupling, we administered NE while ATP
synthase was blocked using oligomycin (state 4o) and showed
that NE only increased mitochondrial uncoupling in brown
adipocytes (from 60.5 ± 4.7 to 187.5 ± 21.4 pmol/min) and not
in white adipocytes (from 72.4 ± 1.8 to 85.3 ± 6.9 pmol/min) (Fig-
ure 4A), illustrating the characteristic uncoupling properties of
‘‘brown’’ (but not white) adipocytes. Thereafter we examined if
CDCA could directly activate BAT. CDCA at 10 mM and 30 mM,
but not at 3 mM, increased oxygen consumption under oligomy-
cin-treated conditions in brown adipocytes, whereas such an
effect was absent in white adipocytes, demonstrating that
CDCA activates BAT (Figures 4B–4D). Of note, the absolute
increase in mitochondrial uncoupling upon 30 mM CDCA was
2-fold (from 62.8 ± 4.1 to 125.9 ± 1.7 pmol/min) and thus lower
when compared to the 3-fold increase upon NE. We also
evaluated the effect of the BA LCA on mitochondrial uncoupling
in the white and brown adipocytes. LCA increasedmitochondrial
uncoupling in brown but not in white adipocytes at 3 and 10 mM422 Cell Metabolism 22, 418–426, September 1, 2015 ª2015 Elsevie(Figures 4E–4G). BAs have been shown to be able to activate
the nuclear receptor FXR and G-coupled protein receptor
TGR5. To investigate the receptors implicated in the uncoupling
effects of CDCA, we used specific FXR and TGR5 agonists.
The TGR5 agonist Compound A (CpdA) increased mitochondrial
uncoupling at 30 mM, specifically in brown adipocytes (Figures
4H and 4I), without an effect in white adipocytes. CpdA displays
high affinity toward TGR5 as measured in a TGR5 activation
assay (Figure S1) and FXR activation assay (Figure S2). In
contrast, the FXR agonist GW4064 did not increase oxygen
consumption in either white or brown adipocytes (Figure 4J).
Consistent with a lack of the FXR agonist on mitochondrial
uncoupling, we were unable to detect FXR mRNA expression
in brown adipocytes (data not shown). These in vitro results
clearly show that specific TGR5 activating compounds have
the potential for mitochondrial uncoupling in human brown
adipocytes, thereby confirming the results of CDCA administra-
tion on BAT activity that were observed in vivo. Interestingly,
the in vitro effect was only observed in primary adipocytes
derived from the human neck region. Although the debate isr Inc.
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Figure 5. CDCA Stimulates the TGR5 Signaling Pathway in BAT In Vitro
(A–C) White and brown adipocytes were stimulated for 24 hr with 3 mM CDCA, 30 mM CDCA, 3 mM LCA, 3 mM TGR5 agonist CpdA, 30 mM TGR5 agonist CpdA,
3 mM INT777, and 3 mMGW4064. Gene expression for D2 (A), UCP1 (B), and TGR5 (C) was determined. *p < 0.05 (n = 3). Results are expressed as mean ± SEM.
See also Figures S1 and S2.still ongoing if these adipocytes belong to the classical BAT or
are an intermediate ‘‘beige’’ adipocyte (Walde´n et al., 2012;
Wu et al., 2012), we clearly demonstrate that the adipocytes
cultured from the adipose tissue of the human BAT region
have a marked different response to CDCA, LCA, TGR5
agonists, and/or NE when compared to ‘‘white’’ adipocytes
cultured from the adipose tissue of subcutaneous fat of the
same donors. Again, this is consistent with our in vivo finding
that CDCA administration only increased glucose uptake in the
BAT region, and not in any other tissue including white adipose
tissue.CDCA Activates the TGR5 Pathway in Human Brown
Adipocytes
Next, we aimed to provide further evidence that CDCA acts via
activation of TGR5 in human brown adipocytes. Activation of
the TGR5 signaling pathway increases cAMP, leading to activa-
tion of D2. Since the amount of human BAT that can be obtained
to culture primary human brown adipocytes is too limited to
perform extensive characterization of the underlying mecha-
nism, we examined whether BA and TGR5 agonists can stimu-
late D2 expression as a proxy of TGR5 stimulation. A 24-hr
treatment with 30 mM CDCA increased D2 expression in human
primary brown adipocytes, whereas 3 mM CDCA was inactive,
in line with its EC50 value for TGR5 activation (Figure 5A); similar
observations were made when brown adipocytes were incu-
bated with the TGR5 agonist CpdA, INT777, or LCA. Again,
GW4064 had no effect on D2 mRNA expression (Figure 5A).
A characteristic of BAT is the ability to uncouple ATP production
via UCP1. Therefore, we next examined if CDCA can alter UCP1
expression in brown adipocytes. A 24-hr treatment with 30 mMTable 2. Subject Characteristics
Age (year) 22 ± 3
BMI (kg) 21.9 ± 1.6
Body mass (kg) 62.2 ± 8.3
Body fat (%) 27.5 ± 6.1
Fat mass (kg) 17.2 ± 4.2
Fat free mass (kg) 43.0 ± 6.6
Values are expressed as means ± SD (n = 12).
Cell MeCDCA increased UCP1 expression, while again no effect
was detected upon 3 mM CDCA (Figure 5B). Similarly, UCP1
expression increased following treatment with the TGR5 ago-
nists CpdA or LCA in brown adipocytes (Figure 5B). The FXR
agonist GW4064 was without effect on UCP1 expression in
brown adipocytes (Figure 5B). TGR5 mRNA expression re-
mained similar following a 24-hr treatment with BA (CDCA,
LCA), TGR5 agonists (CpdA, INT777), or the FXR agonist
GW4064 (Figure 5C). Taken together, these results show that
human primary brown adipocytes increase mitochondrial
uncoupling following CDCA treatment, which is likely dependent
on TGR5 and not FXR. These findings suggest that BAs or
pharmacological activators of TGR5 may be attractive targets
to activate BAT in humans.
In conclusion, the present study shows that administration
of 15 mg/kg body weight CDCA activated BAT under thermo-
neutral conditions; furthermore, the increase in BA was accom-
panied by increased energy expenditure. This effect was
specific for human brown adipocytes and not observed in
white adipocytes. Although more and prolonged intervention
studies are warranted, the BA CDCA seems to be a potential
activator for BAT. Administration of BA supplements may
be an effective method for counteracting obesity and related
metabolic diseases, by increasing BAT activity and potentially
energy expenditure.EXPERIMENTAL PROCEDURES
Subjects
The study was reviewed and approved by the ethics committee of Maastricht
University Medical Center (METC 11-3-029, NL44774.068.13). Written
informed consent was obtained from 13 healthy female subjects. All subjects
were treated according to the standards of the Declaration of Helsinki of 1975,
as revised in 1983. All subjects were studied between February 2014 and June
2014.
A total of 13 healthy female subjects were enrolled in the study. Subject
characteristics are shown in Table 2. All subjects were screened for medical
history and status. Subjects had stable physical activity for at least six months.
All subjects used a specific oral contraceptive pill (levonorgestrel/ethinylestra-
diol) for at least one month prior to participation in the study. Subjects who
were psychologically unstable and subjects with mental retardation or severe
behavior disorders were excluded from the study. Other exclusion criteria
were pregnancy and/or lactation; the use of beta-blockers; the use of urso-
deoxycholic acid, antacids, and/or BA sequestrants; participation in an inten-
sive weight-loss program or vigorous exercise program during the last yeartabolism 22, 418–426, September 1, 2015 ª2015 Elsevier Inc. 423
before the start of the study, and drugs and/or alcohol abuse. Furthermore,
participation in earlier research or medical examinations that include PET/CT
scanning was an exclusion criterion. One subject showed pathological [18F]
FDG uptake in the brown fat regions on the PET/CT scans during both thermo-
neutral conditions. Also, this subject reported sweating and showed inade-
quate thermoregulatory response during cold exposure. This may indicate
that the subject suffered from an autonomous dysregulation, and therefore
the subject was referred to her GP for further investigation and excluded
from further analyses. Study registration: EudraCT number 2013-002512-27.
Study Design
Weused a randomized, double-blinded, placebo-controlled crossover design,
with BAT activity and energy expenditure as primary outcome parameters.
Subjects came to the university for two 2-day intervention periods. On each
occasion, subjects came to the laboratory after an overnight fast. Upon arrival,
first an intravenous catheter was inserted in the antecubital vein, after which
baseline blood samples were taken. Then subjects entered the respiration
room and ingested 15 mg/kg body weight of CDCA or placebo alongside a
standardized breakfast. In the respiration room, energy expenditure was
constantly monitored. During the measurements subjects wore standardized
clothes (socks 0.02 clo, shirt with short sleeves 0.19 clo, sweatpants 0.28
clo, sweatshirt with long sleeves 0.34 clo, underwear 0.04 clo, total clo factor
0.88 clo) (Bligh and Johnson, 1973). The temperature inside the respiration
room was kept constantly at 23C to ensure thermoneutrality. Subjects
received three standardized meals during their 24-hr stay in the respiration
chamber, and subjects remained fasted from 10 p.m. onward. On the next
morning, a blood sample was taken in the overnight-fasted condition, after
which subjects received another dose of 15 mg/kg body weight CDCA or
placebo. Thereafter, subjects were moved to the department of nuclear
medicine and placed on a bed at room temperature (23C). To guarantee a
comfortable position during the measurements, subjects were placed in a
semi-supine position. Indirect calorimetry was used to measure energy
expenditure during the two hours of the measurements. After the first hour
of measurements, 50 MBq of [18F]FDG was injected through a venous cath-
eter. After injection, subjects were instructed to lie still to prevent uptake of
FDG in the muscles. Measurements were continued for another hour, after
which the subject was moved to the PET/CT scanner (Gemini TF PET-CT,
Philips) for quantification of metabolically active BAT. Three hours after
CDCA ingestion, another blood sample was drawn. All measurements were
repeated after one week, and the order of the placebo and CDCA measure-
ments was randomly assigned in a crossover design (Anderson, 1980), so
that each subject received CDCA on one occasion and placebo on the other
occasion. A minimal washout period of 7 days was taken between the exper-
iments. The investigator and subjects were blinded to the treatment allocation
during the experiment.
On a separate day, subjects came to the laboratory after an overnight fast for
the determination of body compensation using dual X-ray absorptiometry
(DXA, Hologic, type Discovery A), and to determinemaximal BAT activity under
cold-exposed conditions, as we have described previously (van der Lans
et al., 2013).
PET Scanning Protocol and Analysis
One hour before the PET-CT scan, subjects were intravenously injected with
50 MBq (1.35 mCi) of [18F]FDG. Imaging started with a low-dose CT scan
(120 kV, 30 mAs), immediately followed by a PET scan. A total of 6–7 bed
positions (5 min per bed position) were necessary to cover the area where
BAT is usually found (i.e., abdominal, thoracic, and neck region). The PET im-
age was used to determine the [18F]FDG uptake, and the CT image was used
for PET attenuation correction and localization of the [18F]FDG uptake sites.
The scans were analyzed using PMOD software (version 3.0; PMOD Tech-
nologies). Two researchers (EPMB, BB) interpreted the PET/CT images.
We used the fixed-volume method (van der Lans et al., 2014) to determine
the average standard uptake value (SUV mean) and maximum standard up-
take value (SUV max) in pairs of right- and left-sided volumes of interest
(VOIs) of 83838mm size. Analyses were carried out on scans after cold expo-
sure, placebo, and CDCA intervention. VOIs were placed and analyzed in
supraclavicular BAT, subcutaneous WAT, skeletal muscle, liver, and brain.
The same anatomic locations were used in the analysis between all three424 Cell Metabolism 22, 418–426, September 1, 2015 ª2015 Elsevieexperiments, as described earlier by our group (van der Lans et al., 2014).
The SUV of BAT was measured and averaged over the right and left supracla-
vicular fat depots by placing the VOIs right and left in the area ofmaximumSUV
activity within the depot, with verification of fat tissue by appropriate negative
Hounsfield units (HU) for fat tissue. To determine the average [18F]FDG uptake
in the deltoid muscle and the triceps and biceps muscle, we analyzed the
middle (thickest) part of these muscles in both arms. The uptake in the erector
spinae muscle was measured in the cervical (C-7), thoracic (Th-8), and lumbar
(L-3) part of the muscle. The subcutaneous WAT was measured in the
dorsolumbar region near vertebra L-3. Themiddle part of the liver was selected
for analysis of liver uptake, and we avoided uptake in the large blood vessels
by carefully distinguishing between the liver segments. Adipose tissue
was distinguished from muscle tissue by means of HU on CT scan (adipose
tissue 10 to 180 HU, skeletal muscle 15 to 100) (van der Lans et al.,
2013; Vosselman et al., 2012).
Blood Analysis
Blood was collected from the antecubital vein for analyses of several blood
variables. Plasma concentrations of free fatty acids (NEFA-HR set; Wako
Chemicals), free glycerol (Glycerol kit; R-Biopharm), total glycerol (ABX Trigly-
ceriden CP; Horiba ABX), and glucose (ABXGlucose HKCP; Horiba ABX) were
measured on a COBAS PENTRA centrifugal spectrophotometer (Horiba ABX).
Plasma triglyceride concentrations were calculated by subtracting free
glycerol from the total glycerol concentrations, and serum insulin was analyzed
on a Gamma Counter (2470 Automatic Gamma Counter Wizard2 Wallac;
Perkin-Elmer) with a Human Insulin specific RIA kit (Millipore). Serum TSH
was measured by an Electrochemiluminescence Immunoassay Kit on a
COBAS 6000 system (Roche Diagnostica), and free thyroxine (FT4) was
analyzed by a solid-phase time-resolved fluoroimmunoassay kit on an
AutoDELFIA system (PerkinElmer). Plasma inflammatory marker C- reactive
protein (CRP) was measured with a particle-enhanced immunoturbidimetric
assay on a COBAS PENTRA system (Horiba ABX). BA concentrations were
determined in plasma by phase liquid chromatography associated to tandem
mass spectrometry (LC-MS/MS, inMultiple ReactionMonitoring [MRM]mode)
after extraction by protein precipitation. The use of internal deutered standards
allowed the quantification.
Human Primary Adipocyte Cultures
The collection of stromal vascular fraction was obtained from BAT and subcu-
taneous white adipose tissue from the same individual during thyroid surgery
in patients with a normal thyroid function using a collagenase digestion and
was reviewed and approved by the ethics committee of Maastricht University
Medical Center (METC 10-3-012, NL31367.068.10).
Written informed consent (n = 4) was obtained before surgery. Collected
cells were grown to confluence before differentiationwas initiated. The stromal
vascular fraction derived from BAT was incubated with bFGF (4 ng/ml) during
2 days before confluence was achieved. Differentiation was initiated for 7 days
via differentiationmediummade up out of biotin (33 mM), pantothenate (17 mM),
insulin (100 nM), dexamethasone (100 nM), IBMX (250 mM), rosiglitazone
(5 mM), T3 (2 nM), and transferrin (10 mg/ml). Specifically for the differentiation
of the stromal vascular fraction derived from BAT, BMP4 (4 ng/ml) was
included in the differentiation medium. Cells were transferred to maintenance
medium consisting of biotin (33 mM), pantothenate (17 mM), insulin (100 nM),
dexamethasone (10 nM), T3 (2 nM), and transferrin (10 mg/ml) until mature ad-
ipocytes had formed.
In Vitro Oxygen Consumption in Differentiated Adipocytes
The stromal vascular fraction derived from adipose tissue biopsies was plated
in XF96-well cell culture plate. After cells were differentiated into mature
adipocytes as described in the previous section, oxygen consumption and
mitochondrial function were measured using the XF96 extracellular flux
analyzer from Seahorse Biosciences. Cells were incubated for 1 hr at 37C
in unbuffered DMEM (2 mM GlutaMAX, 1 mM sodium pyruvate, 1.85 gl1
NaCl, and 25 mM glucose). Basal oxygen consumption was measured
followed by injection of 2 mM oligomycin and subsequently followed by injec-
tion of the compounds of interest. Oligomycin and CDCA, GW4064, and LCA
were purchased from Sigma-Aldrich. The TGR5 agonist CpdA 3-(2,6-difluoro-
benzylthio)-5-(3,4-dimethoxybenzyl)-4-(4-fluorophenyl)-4H-1,2,4-triazole wasr Inc.
synthetized according to patent WO2010/093845. Data are plotted as a per-
centage compared to uncoupled respiration following oligomycin.
RNA Isolation and Gene Expression Analysis
Total RNA was extracted from mature adipocytes using the miRNEasy kit
from QIAGEN according to the manufacturer. cDNA was created using the
high-capacity RNA-to-cDNA-kit from Applied Biosystems. Gene expression
data were normalized to TATA box-binding protein (TBP) and further analyzed
using the 2DDCt method. Primers for D2 (Hs00988260_m1) and UCP1
(Hs00222453_m1) were from Applied Biosystems. SYBR-green qPCR primers
were as follows: PGC1a: forward primer 50-TGCTGAAGAGGGAAAGTGA
GCGATTAGTTGA-30, reverse primer 50-AGGTGAAAGTGTAATACTGTTGGTT
GA-30; AP2 (FABP4): forward primer 50-CCTTTAAAAATACTGAGATTTCCT
TCA-30, reverse primer 50-GGACACCCCCATCTAAGGT-30; HOXC9: forward
primer 50-GGACTCGCTCATCTCTCACG-30, reverse primer 50-AAAATCGCTA
CAGTCCGGCA-30; TGR5: forward primer 50-CAGTGTCGACCTGGACTTGA-
30, reverse primer 50-TAACGGCCAGAGGAGCTTTA-30. Primers for TBP and
TBX1 have been described previously (Wu et al., 2012).
Western Blot Analysis
Brown adipocytes were harvested in Laemmli buffer. Proteins were separated
using SDS-PAGE followed by transfer to nitrocellulose membranes. Proteins
were detected and quantified using the Odyssey from LI-COR Biosciences.
The antibody againstUCP1 (ab10983) was purchased fromAbcam. Beta-actin
(A5316) was detected using an antibody from Sigma-Aldrich.
Statistical Analysis
Statistical analysis was performed by PASW Statistics version 20.0 for
MacBook Pro. Reported data are expressed as means ± SD where indicated.
The primary endpoints in this study were BAT activity and energy expenditure.
Total BAT activity was expressed in kBq and standard uptake values (SUV; as
calculated by uptake [kBq/ml] per injected dose [kBq] per patient weight [g]).
BAT activity of each region was determined by the average SUV (SUV mean)
times the volume of the region (cubic centimeter), expressed as SUV total.
Repeated measurements were compared using Student’s t test. p values
of < 0.05 were considered statistically significant. Group size estimations
were based upon a power calculation to minimally yield an 80% chance to
detect a significant difference in BAT activity and EE of p < 0.05 between
the treatments. For qPCR analysis, differences between two means were
analyzed using a Student’s t test. For respiration experiments, differences
were analyzed using a two-way ANOVA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.cmet.2015.07.002.
AUTHOR CONTRIBUTIONS
E.P.M.B. and E.B.M.N. designed and performed the experiments, analyzed
data, and wrote the manuscript. KH.M.R. and G.S. assisted during the exper-
iments. B.H., B.B., N.D.B, F.M., B.S., W.D.v.M.L, and P.S. contributed to the
design of the study, analyzed and interpreted the data, and reviewed and edi-
ted the manuscript. A.T. and M.K. performed the analyses of total bile acids
and bile acid profiles. B.D. and J.C. synthetized the CpdA. All authors
approved the final version of the manuscript.
CONFLICTS OF INTEREST
The authors report no conflicts of interest relevant to this article.
ACKNOWLEDGMENTS
This work is partly financed by the Netherlands Organization for Scientific
Research (TOP 91209037 to W.D.v.M.L.) and by the EU FP7 project DIABAT
(HEALTH-F2-2011-278373). B.S. is a member of the Institut Universitaire de
France. The authors thank Lauren Sparks, Adeline Divoux (Translational
Research Institute for Metabolism and Diabetes), and Jun Wu (Life SciencesCell MeInstitute) for assistance during the in vitro experiments and Jos Stegen (Maas-
tricht University Medical Center), Hasibe Aydeniz (Maastricht University Med-
ical Center), Esther Kornips (Maastricht University Medical Center), Johanna
Jo¨rgensen (Maastricht University Medical Center), the Biobank (Maastricht
University Medical Center), Renate Hensen-Lodewijk (Radboud University
Medical Center), Jan Verhagen (Radboud University Medical Center), and
Nancy Hendrix (Maastricht University Medical Center) for assistance with the
biochemical analysis. The authors further acknowledge Marike van Gisbergen
(Maastro lab, Maastricht University) for assistance with the respiration exper-
iments. The authors also thankMarie¨lle Visser, RoelWierts and the department
of Nuclear Medicine, Loek Wouters, and Paul Schoffelen for technical support
and the Literature Club for all of the fruitful discussions.
Received: December 17, 2014
Revised: April 1, 2015
Accepted: July 1, 2015
Published: July 30, 2015
REFERENCES
Ahmad, N.N., Pfalzer, A., and Kaplan, L.M. (2013). Roux-en-Y gastric bypass
normalizes the blunted postprandial bile acid excursion associated with
obesity. Int J Obes (Lond) 37, 1553–1559.
Anderson, R.L. (1980). William Gemmell Cochran 1909-1980. A personal
tribute. Biometrics 36, 575–578.
Bartelt, A., Bruns, O.T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K.,
Kaul, M.G., Tromsdorf, U.I., Weller, H., Waurisch, C., et al. (2011). Brown ad-
ipose tissue activity controls triglyceride clearance. Nat. Med. 17, 200–205.
Bligh, J., and Johnson, K.G. (1973). Glossary of terms for thermal physiology.
J. Appl. Physiol. 35, 941–961.
Brufau, G., Bahr, M.J., Staels, B., Claudel, T., Ockenga, J., Bo¨ker, K.H.,
Murphy, E.J., Prado, K., Stellaard, F., Manns, M.P., et al. (2010). Plasma bile
acids are not associated with energy metabolism in humans. Nutr. Metab.
(Lond) 7, 73.
Cannon, B., and Nedergaard, J. (2004). Brown adipose tissue: function and
physiological significance. Physiol. Rev. 84, 277–359.
Chen, X., Lou, G., Meng, Z., and Huang, W. (2011). TGR5: a novel target for
weight maintenance and glucose metabolism. Exp. Diabetes Res. 2011,
853501.
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B.,
Kuo, F.C., Palmer, E.L., Tseng, Y.H., Doria, A., et al. (2009). Identification
and importance of brown adipose tissue in adult humans. N. Engl. J. Med.
360, 1509–1517.
De Giorgi, S., Campos, V., Egli, L., Toepel, U., Carrel, G., Cariou, B., Rainteau,
D., Schneiter, P., Tappy, L., and Giusti, V. (2014). Long-term effects of Roux-
en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in fe-
male non diabetic subjects: A cross-sectional pilot study. Clin. Nutr. Published
online September 26, 2014. http://dx.doi.org/10.1016/j.clnu.2014.09.018.
Fiorucci, S., Mencarelli, A., Palladino, G., and Cipriani, S. (2009). Bile-acid-
activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and
glucose disorders. Trends Pharmacol. Sci. 30, 570–580.
Fu, L., John, L.M., Adams, S.H., Yu, X.X., Tomlinson, E., Renz, M., Williams,
P.M., Soriano, R., Corpuz, R., Moffat, B., et al. (2004). Fibroblast growth factor
19 increasesmetabolic rate and reverses dietary and leptin-deficient diabetes.
Endocrinology 145, 2594–2603.
Hofmann, A.F. (2009). Bile acids: trying to understand their chemistry and
biology with the hope of helping patients. Hepatology 49, 1403–1418.
Houten, S.M., and Auwerx, J. (2004). The enterohepatic nuclear receptors are
major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36,
482–491.
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M.,
Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003). A G protein-
coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435–9440.
Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K.,
Xu, H.E., Shulman, G.I., Kliewer, S.A., and Mangelsdorf, D.J. (2011). FGF19tabolism 22, 418–426, September 1, 2015 ª2015 Elsevier Inc. 425
as a postprandial, insulin-independent activator of hepatic protein and
glycogen synthesis. Science 331, 1621–1624.
Kohli, R., Bradley, D., Setchell, K.D., Eagon, J.C., Abumrad, N., and Klein, S.
(2013).Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic
adjustable gastric banding increases circulating bile acids. J. Clin. Endocrinol.
Metab. 98, E708–E712.
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., and Staels, B. (2009). Role of bile
acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89,
147–191.
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama,
E., Nakamura, T., Itadani, H., and Tanaka, K. (2002). Identification of mem-
brane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res.
Commun. 298, 714–719.
Miyata, M., Hata, T., Yamakawa, H., Kagawa, T., Yoshinari, K., and Yamazoe,
Y. (2012). Involvement of multiple elements in FXR-mediated transcriptional
activation of FGF19. J. Steroid Biochem. Mol. Biol. 132, 41–47.
Muzik, O., Mangner, T.J., and Granneman, J.G. (2012). Assessment of oxida-
tive metabolism in brown fat using PET imaging. Front. Endocrinol. (Lausanne)
3, 15.
Ockenga, J., Valentini, L., Schuetz, T., Wohlgemuth, F., Glaeser, S., Omar, A.,
Kasim, E., duPlessis, D., Featherstone, K., Davis, J.R., et al. (2012). Plasma bile
acids are associated with energy expenditure and thyroid function in humans.
J. Clin. Endocrinol. Metab. 97, 535–542.
Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Noponen, T., Viljanen, T.,
Scheinin, M., Taittonen, M., Niemi, T., Enerba¨ck, S., and Virtanen, K.A.
(2011). Different metabolic responses of human brown adipose tissue to acti-
vation by cold and insulin. Cell Metab. 14, 272–279.
Patti, M.E., Houten, S.M., Bianco, A.C., Bernier, R., Larsen, P.R., Holst, J.J.,
Badman, M.K., Maratos-Flier, E., Mun, E.C., Pihlajamaki, J., et al. (2009).
Serum bile acids are higher in humans with prior gastric bypass: potential
contribution to improved glucose and lipid metabolism. Obesity (Silver
Spring) 17, 1671–1677.
Prawitt, J., and Staels, B. (2010). Bile acid sequestrants: glucose-lowering
mechanisms. Metab. Syndr. Relat. Disord. 8 (1), S3–S8.
Russell, D.W. (2003). The enzymes, regulation, and genetics of bile acid syn-
thesis. Annu. Rev. Biochem. 72, 137–174.
Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T.,
Nio-Kobayashi, J., Iwanaga, T., Miyagawa, M., Kameya, T., Nakada, K., et al.
(2009). High incidence of metabolically active brown adipose tissue in healthy
adult humans: effects of cold exposure and adiposity. Diabetes 58, 1526–
1531.
Simonen, M., Dali-Youcef, N., Kaminska, D., Venesmaa, S., Ka¨kela¨, P.,
Pa¨a¨kko¨nen, M., Hallikainen, M., Kolehmainen, M., Uusitupa, M., Moilanen,
L., et al. (2012). Conjugated bile acids associate with altered rates of glucose
and lipid oxidation after Roux-en-Y gastric bypass. Obes. Surg. 22, 1473–
1480.426 Cell Metabolism 22, 418–426, September 1, 2015 ª2015 ElsevieStaels, B., and Prawitt, J. (2013). Soaping up type 2 diabetes with bile acids?:
the link between glucose and bile acid metabolism in humans tightens: quality
matters! Diabetes 62, 3987–3989.
Teodoro, J.S., Zouhar, P., Flachs, P., Bardova, K., Janovska, P., Gomes, A.P.,
Duarte, F.V., Varela, A.T., Rolo, A.P., Palmeira, C.M., and Kopecky´, J. (2014).
Enhancement of brown fat thermogenesis using chenodeoxycholic acid in
mice. Int J Obes (Lond) 38, 1027–1034.
Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan,
J.P., Tsai, S.P., Powell-Braxton, L., French, D., and Stewart, T.A. (2002).
Transgenic mice expressing human fibroblast growth factor-19 display
increased metabolic rate and decreased adiposity. Endocrinology 143,
1741–1747.
van der Lans, A.A., Hoeks, J., Brans, B., Vijgen, G.H., Visser, M.G., Vosselman,
M.J., Hansen, J., Jo¨rgensen, J.A., Wu, J., Mottaghy, F.M., et al. (2013). Cold
acclimation recruits human brown fat and increases nonshivering thermogen-
esis. J. Clin. Invest. 123, 3395–3403.
van der Lans, A.A., Wierts, R., Vosselman, M.J., Schrauwen, P., Brans, B., and
van Marken Lichtenbelt, W.D. (2014). Cold-activated brown adipose tissue in
human adults: methodological issues. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 307, R103–R113.
van Marken Lichtenbelt, W.D., Vanhommerig, J.W., Smulders, N.M.,
Drossaerts, J.M., Kemerink, G.J., Bouvy, N.D., Schrauwen, P., and Teule,
G.J. (2009). Cold-activated brown adipose tissue in healthy men. N. Engl. J.
Med. 360, 1500–1508.
Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T.,
Taittonen, M., Laine, J., Savisto, N.J., Enerba¨ck, S., and Nuutila, P. (2009).
Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360,
1518–1525.
Vosselman, M.J., van der Lans, A.A., Brans, B., Wierts, R., van Baak, M.A.,
Schrauwen, P., and van Marken Lichtenbelt, W.D. (2012). Systemic b-adren-
ergic stimulation of thermogenesis is not accompanied by brown adipose tis-
sue activity in humans. Diabetes 61, 3106–3113.
Walde´n, T.B., Hansen, I.R., Timmons, J.A., Cannon, B., and Nedergaard, J.
(2012). Recruited vs. nonrecruited molecular signatures of brown, ‘‘brite,’’
and white adipose tissues. Am. J. Physiol. Endocrinol. Metab. 302, E19–E31.
Watanabe, M., Houten, S.M., Mataki, C., Christoffolete, M.A., Kim, B.W., Sato,
H., Messaddeq, N., Harney, J.W., Ezaki, O., Kodama, T., et al. (2006). Bile
acids induce energy expenditure by promoting intracellular thyroid hormone
activation. Nature 439, 484–489.
Wu, J., Bostro¨m, P., Sparks, L.M., Ye, L., Choi, J.H., Giang, A.H., Khandekar,
M., Virtanen, K.A., Nuutila, P., Schaart, G., et al. (2012). Beige adipocytes are a
distinct type of thermogenic fat cell in mouse and human. Cell 150, 366–376.
Yoneshiro, T., Aita, S., Matsushita, M., Kayahara, T., Kameya, T., Kawai, Y.,
Iwanaga, T., and Saito, M. (2013). Recruited brown adipose tissue as an anti-
obesity agent in humans. J. Clin. Invest. 123, 3404–3408.r Inc.
